Skip to main content
Equibles

TARSONS · Tarsons Products Limited

Use TARSONS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TARSONS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
316.40 INR +4.40 (+1.41%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 5653 Avg daily vol (3M) 17.66K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close316.40 INR Open300.25 INR Day300.25–324.20 INR 52W close166.75–364.10 INR Avg vol 30d7K Last earningsNov 13, 2026 DataNov 2021–Nov 2026

Latest documents

2026
Nov 13
Earnings call
Revenue growth exceeds 20% for second consecutive quarter

Tarsons Products Limited reported Q2 F527 standalone revenue growth of 25% and consolidated growth of 21% YOY, marking its second consecutive quarter of over 20% revenue growth, driven mainly by existing products and pharma and healthcare demand.

2 source passages
Good afternoon, everybody, and a warm welcome to the Q2 and H1FI27 earnings call of Tarsons Products Limited. We are pleased to deliver another quarter of strong performance, where our standalone revenue grew by 25% and consolidated revenue grew by 21% in Q2 F527 on a YOY basis. This marks our second consecutive quarter of over 20% revenue growth, reflecting the resilience of our business model, strong execution capabilities, Diversified product portfolio and branch length. Importantly, growth was largely driven by our existing product portfolio, with minimal contribution from new product categories. The uptick in inquiries, better customer engagement, and improvement in the demand momentum across our end-user industries, especially in the pharma and healthcare industry. Gives us the confidence that demand trajectory has the potential to sustain. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲54.8% 956.77M INR 0 INR '25 Q3 ▲6.6% 1.13B INR 0 INR '25 Q4 ▲7.7% 913.64M INR 0 INR '26 Q1 ▲3.1% 1.02B INR 0 INR '26 Q2 ▲12.8% 1.08B INR 0 INR '26 Q3 ▲7.3% 1.21B INR 0 INR '26 Q4 ▲20.7% 1.10B INR 0 INR '27 Q1 LATEST ▲20.8% 1.24B INR 0 INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 166.75 INR Now 316.40 INR · 76% Range high 364.10 INR
vs 200-day avg +22% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:TARSONS -0.3% -3.3% +45.3% +8.5% +35.6%

Exchange listing

Market
XBOM
Ticker
TARSONS
ISIN
INE144Z01023
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.tarsons.com/
Investor relations
https://www.tarsons.com/financial-reports/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2024-09-20 2.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-13 Audio Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-11 Audio Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-25 Audio Transcript
    Earnings Call for the Quarter Ended March 31, 2026